# Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

> **NCT02225665** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **GENETIC:** SB-728mR-T
- **GENETIC:** SB-728mR-T
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02225665
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225665, "Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02225665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*